New Search

If you are not happy with the results below please do another search

Search
Generic filters

50 search results for:

2

Abbott Labs to pay $160 million over kickbacks, false diabetes claims to Medicare

Abbott Laboratories will pay $160 million to resolve claims that two of the company’s units submitted false claims to Medicare by providing kickbacks to diabetes patients, including “free” or “no cost” glucose monitors, the U.S. Department of Justice said.

3

Ipsen Strikes $1 Billion+ Deal For Exicure’s Oligonucleotides

Ipsen, a global biopharmaceutical firm that specializes in neuroscience, oncology and rare diseases, partnered with Exicure, a clinical-stage biotech company that develops treatments for neurological, inflammatory and genetic disorders, to create new therapies for Angelman syndrome (AS) and Huntington’s disease (HD).

4

AbbVie Posts Strong Second Quarter as Rinvoq Gears Up to Succeed Humira

AbbVie’s Rinvoq continues to demonstrate the medicine’s clinical potential to become the heir-apparent to the company’s blockbuster drug Humira, which will lose patent protection in 2023. In the company’s second-quarter 2021 report, AbbVie touted advances Rinvoq made throughout the three months, including positive Phase III data in ulcerative colitis.

5

Delta spreads ‘like wildfire’ as doctors study whether it makes patients sicker

With a new wave of Covid-19 infections fueled by the Delta variant striking countries worldwide, disease experts are scrambling to learn whether the latest version of coronavirus is making people – mainly the unvaccinated – sicker than before.